More than 40% of patients with ulcerative colitis taking vedolizumab achieved disease clearance at 16 weeks of treatment during the VERDICT trial, according to findings presented at the 2024 European Crohn’s and Colitis Congress.
The preliminary data are part of the ongoing trial, which is aiming to determine the optimal treatment target in moderate to severe active UC.
Disease clearance, as defined in the study, is the concurrent achievement of clinical, endoscopic and histologic